Combined intravitreal ranibizumab and grid laser photocoagulation for branch retinal vein occlusion with macular edema

( views:403, downloads:0 )
Author:
ZHENG Hong-mei(Eye Center, Renmin Hospital of Wuhan University, Wuhan 430060, China)
XING Yi-qiao(Eye Center, Renmin Hospital of Wuhan University, Wuhan 430060, China)
CHEN Chang-zheng(Eye Center, Renmin Hospital of Wuhan University, Wuhan 430060, China)
()
Journal Title:
Chinese Journal of Ocular Fundus Diseases
Issue:
Volume 28, Issue 05, 2012
DOI:
10.3760/cma.j.issn.1005-1015.2012.05.010
Key Word:
Retinal vein occlusion/therapy; Antibodies, monoclonal/therapeutic use; Laser coagulation

Abstract: Objective To observe the effectiveness of combined therapy of intravitreal injections of ranibizumab and macular grid laser photocoagulation for branch retinal vein occlusion (BRVO) with macular edema (ME).Methods Forty-six patients of BRVO with ME were enrolled in this study.All the patients were examined for corrected visual acuity of Early Treatment Diabetic Retinopathy Study (ETDRS),slit lamp microscope,direct ophthalmoscope,intraocular pressure,fundus color photography,fundus fluorescein angiography and optical coherence tomography.The patients were divided into three groups by different treatments:injection group (18 eyes) received intravitreal injections of ranibizumab only,joint group (17 eyes) received intravitreal injections of ranibizumab combined with grid laser photocoagulation,and laser group (11 eyes) received laser photocoagulation only.The follow-up ranged from three to 15 months,with a mean of (8.0±3.2) months.The same equipment and methods were used to return visit in follow-up period.Repeated injections were adopted in injection group and joint group according to the results of subsequent visits.Then the repeated times of injection in two groups were compared.The visual acuity,macular retinal thickness (CRT) and ocular and systemic adverse reactions about drugs and treatments were followed up.The last follow-up time was considered as the judgment time for the therapeutic effects.Results The mean repeat times of injection in the injection group was 5.4±0.4,which more than that in the joint group 3.2±0.6 (t =12.17,P<0.05).No ocular or systemic adverse events were observed in follow-up period.ETDRS visual acuity of injection group,joint group and laser group increased by 7.30 ± 8.68,8.50±6.04,1.55±6.85 letters respectively after treatment.The differences were statistically significant before and after treatment in injection group and joint group (t=3.58,5.78; P<0.05),but there was no significant difference in laser group (t=0.75,P>0.05).The difference was not statistically significant between injection group and joint group (t=0.45,P>0.05).The difference was statistically significant between injection group and laser group,but also between joint group and laser group (t=2.13,2.81; P<0.05).CRT of injection group,joint group and laser group decreased by (110.56±43.08),(125.47±35.19),(50.73 ± 19.68) μm respectively after treatment,with statistically significant differences ( t =-10.89,-14.70,-8.55; P< 0.05).Conclusion In the treatment of BRVO with ME,intravitreal injection of ranibizumab combined with macular grid laser photocoagulation can reduce repeat times of injection,improve visual function and relieve ME.

  • [1]张惠蓉,夏英杰.视网膜静脉阻塞患者视力预后相关因素分析.中华眼科杂志,2002,38:98-102.
  • [2]绳月华,张承芬,陈有信,等.视网膜分支静脉阻塞激光治疗及随诊观察.中华眼底病杂志,2001,17:15-16.
  • [3]Esrick E,Subramanian ML,Hcier JS,et al.Multiple laser treatments for macular edema attributable to branch retinal vein occlusion.Am J Ophthalmol,2005,139:653-657.
  • [4]彭晓燕,张水鹏.糖尿病视网膜病变的治疗趋势.眼科,2011,20:217-221.
  • [5]Heier JS,Campochiaro PA,Yau L,et al.Ranibizumah for macular edema due to retinal vein occlusions:long-term follow-up in the HORIZON trial.Ophthalmology,2012,119:802-809.
  • [6]喻晓兵,师自安,戴虹,等.曲安奈德玻璃体注射治疗视网膜分支静脉阻塞继发黄斑水肿.中国实用眼科杂志,2006,24:1043-1045.
  • [7]钱彤,黎晓新,尹虹,等.玻璃体腔注射avastin治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察.眼科研究,2010,28..79-82.
  • [8]Arevalo JF,Fromow-Guerra J,Sanchez JG,et al.Primary int ravit real bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration:results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.Retina,2008,28:1387-1394.
  • [9]Mansour AM,Shahin M,Kofoed PK,et al.Insight into 144patients with ocular vascular events during VEGF antagonist injections.Clin Ophthalmol,2012,6:343-363.
  • [10]Azad R,Vivek K,Sharma Y,et al.Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion.Indian J Ophthalmol,2012,60:263-266.
  • [11]黎晓新.多波长激光//黎晓新,廖菊生.眼底病激光治疗指南.北京:人民卫生出版社,2009:2-21.
  • [12]Noma H,Funatsu H,Yamasaki M,et al.Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.Am J Ophthalmol,2005,140:256-261.
  • [13]Paul M,Francesco B,Ursula S,et al.Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.Ophthalmology,2011,118:615-625.
  • [14]Donati S,Barosi P,Bianchi M,et al.Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.Eur J Ophthalmol,2012,22:607-614.
  • [15]Salinas Alamán A,Zarranz Ventura J,Caire González Jauregui JM,et al.Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion.Eur J Ophthalmol,2011,21:434-439.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn